secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2026-08-06T20:01:21+00:00
Accession:  0001171843-26-005316
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex Q2 net loss $73.5M; barzolvolimab Phase 3 CSU topline data expected Sept/Oct 2026
--------------------------------------------------------------------------------

- Net loss of $73.5M ($0.94/share) vs $56.6M in Q2 2025; no material revenue.
- Cash $717.6M after $323.8M public offering; runway through 2028.
- Barzolvolimab Phase 3 CSU enrolled 1,939 patients; topline data Sept/Oct 2026; BLA planned 2027.
- Phase 2 prurigo nodularis study failed primary endpoints; discontinued.
- CDX-622 Phase 1 showed rapid tryptase reduction; asthma POM study ongoing; expanding into allergic rhinitis and food allergy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/0001171843-26-005316-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000117184326005316/f8k_080626.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-005316

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer